B
BCWorldPharm Co Ltd
KOSDAQ:200780
BCWorldPharm Co Ltd
KOSDAQ:200780
Price:
4 685
KRW
1.74%
Market Closed
Market Cap:
₩50B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
C
|
Chinney Alliance Group Ltd
XBER:CJJ2
|
HK |
BCWorldPharm Co Ltd
Non-Reccuring Items
Last
Value
3 Years
3Y
CAGR
5 Years
5Y
CAGR
10 Years
10Y
CAGR
|
See Also
BCWorldPharm Co Ltd
Non-Reccuring Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Non-Reccuring Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
BCWorldPharm Co Ltd
KOSDAQ:200780
|
Non-Reccuring Items
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Yuhan Corp
KRX:000100
|
Non-Reccuring Items
₩79.8B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
17%
|
|
|
SK Biopharmaceuticals Co Ltd
KRX:326030
|
Non-Reccuring Items
₩597.3m
|
CAGR 3-Years
-48%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Hanmi Pharm Co Ltd
KRX:128940
|
Non-Reccuring Items
-₩3B
|
CAGR 3-Years
14%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
14%
|
|
|
S
|
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
|
Non-Reccuring Items
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
C
|
Caregen Co Ltd
KOSDAQ:214370
|
Non-Reccuring Items
₩0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
No Stocks Found
BCWorldPharm Co Ltd
Glance View
BCWORLD PHARM.Co., Ltd. engages in the manufacture and development of pharmaceutical products. The company is headquartered in Yeoju, Gyeonggi-Do. The company went IPO on 2014-12-15. The firm's products include anesthetic pain medication such as cancer pain treatment, muscle relaxants, anesthesia and pain relief drugs; circulation contracts such as hypertension and hyperlipidemia; antibiotics such as tuberculosis treatment; other prescription drugs such as peptic ulcer and osteoporosis. In addition, the Company develops improved drugs and new products.
Intrinsic Value
5 422.46
KRW
Undervaluation 14%
B
